spacer
home > ebr > spring 2018 > beyond the genome
PUBLICATIONS
European Biopharmaceutical Review

Beyond the Genome

The epigenome may hold the key to precision medicine, revealing critically important chemical modifications within DNA that alter the structure, function, and regulation of genes. This exciting and rapidly evolving area brings new perspectives to fundamental biological processes underpinning human disease, development, and ageing. Targeting of precise and powerful epigenetic mechanisms may advance personalised medicine beyond the realms of genomics, bringing opportunities for novel therapeutics and diagnostics that will improve patient outcomes and make efficient use of healthcare resources.

Epigenetic modifications within genomes do not alter the underlying sequence of DNA. Instead, precise chemical changes to DNA or RNA nucleotides and histone proteins alter the regulation and function of genes. Epigenetic modifications are inheritable and can be added or removed in response to specific external factors. Patient’s lifestyles (such as smoking and diet), environment, and the stressors that people are exposed to influence the dynamic structure and function of epigenomes, impacting the delicate balance of chemical modifications that are essential to numerous cellular processes.

Informative Diagnostics

Dysregulation of epigenetic pathways can have disastrous consequences; mutations within epigenetic regulators are among the most prevalent across all cancers (1). In addition to cancers, changes within the epigenome are associated with development of a wide range of diseases and health conditions, including neurological and metabolic diseases (2).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Jason Mellad is the CEO at Cambridge Epigenetix, which aims to change the way medicine is practised by reducing several routine and important diagnostic screening tests to a simple blood draw using the power of 5hmC epigenetic modification. Jason has a BSc in molecular biology and chemistry from Tulane University, US, and was a Marshall Scholar at the University of Cambridge, UK, where he completed a PhD in medicine.
spacer
Dr Jason Mellad
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

BioIVT to Focus on the Application of In Vitro Hepatocyte Models in Toxicology Research at the North American ISSX Meeting

BioIVT, a leading provider of research models and services for drug development, today announced that it will be participating in several sessions at the 22nd North American International Society for the Study of Xenobiotics (ISSX) Meeting. This conference will be held from July 15-19 at the Palais des congrès de Montréal in Montréal, Canada.
More info >>

White Papers

Blockbuster Drugs Need Blockbuster Components

West Pharmaceutical Services, Inc.

Many of the world’s blockbuster drugs are now delivered via a prefilled syringe system or auto-injector. To ensure patient safety, pharmaceutical manufacturers need high-quality components that feature reduced particulates and ensure consistency of delivery while fitting the changing needs of higher-volume delivery systems.
More info >>

 
Industry Events

SCOPE Europe: Summit for Clinical Ops Executives

16-17 October 2018, Barcelona, Spain

Building on the success of its long-running US-based counterpart, Summit for Clinical Trials Operations Executives Europe (SCOPE Europe) is a two-day event serving clin ops execs, functional heads, category managers and those responsible for the planning and management of clinical trials in Europe and the Rest of the World.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement